SUPN earnings call for the period ending December 31, 2018.
News & Analysis: Supernus Pharmaceuticals
Think software-as-a-service, neurology drugs, and marijuana.
Find out why our healthcare contributors believe that these biotechs are great buys right now.
Sometimes good news just isn't good enough.
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
These three relatively small biotechs could be just the ticket.
Shares sell off after the company posts mixed second-quarter results. Here's what investors need to know.
Despite Supernus' strong third-quarter earnings report, two possible concerns send the stock tumbling.
A change to phase 3 trials evaluating its lead product candidate SPN-810 fueled investors' pessimism.
On the hunt for a few stocks that hold upside potential? Here's why you should consider Starbucks, Wynn Resorts, and Supernus Pharmaceuticals.